Tools & Techniques News

Scientists combined engineered E. coli with artificial intelligence to produce effective, high-quality protein and antibody-based drugs at a large scale.

A biopharmaceutical company established a new method for isolating and editing hematopoietic stem cells from patients to provide stem cell therapies for diseases such as sickle cell disease.

Beyond the buzz, is AI just another research tool?

Researchers built a framework to purposefully identify drug candidates for repurposing.

Pivotal advancements in transgenic science in the 1970s and 80s helped launch the mouse as a model system for studying human development and disease.

By fusing a brain-targeted antibody with an antibody that protects neurons from degeneration, scientists developed a new class of drugs that can traverse the blood brain barrier, enabling potential new treatments for Parkinson’s disease, Alzheimer’s disease, and depression.

Single-nucleotide polymorphisms (SNPs) occur where a single base pair at a specific locus differs from the standard sequence. The SNP might relate to disease susceptibility, pathogenesis of disease, or efficacy of specific drugs. Identifying SNPs is useful for improving our understanding of human genetics and as a clinical diagnostic tool.

Targeting oncogenic transcription factors like MYC is challenging, but researchers found a way to target its regulator, WDR5, for degradation, exemplifying the capacity of protein degraders to target the “undruggable.”

From excising integrated viral sequences to modifying stem cells, CRISPR offers new possibilities for developing HIV treatments.